Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311503457> ?p ?o ?g. }
- W4311503457 abstract "Current guidelines recommend a higher-dose inhaled corticosteroids (ICS) or adding a long-acting muscarinic antagonist (LAMA) when asthma is not controlled with medium-dose (MD) ICS/long-acting beta2-agonist (LABA) combination therapy.To assess the effectiveness and safety of dual (ICS/LABA) and triple therapies (ICS/LABA/LAMA) compared with each other and with varying doses of ICS in adolescents and adults with uncontrolled asthma.We searched multiple databases for pre-registered randomised controlled trials (RCTs) of at least 12 weeks of study duration from 2008 to 18 February 2022.We searched studies, including adolescents and adults with uncontrolled asthma who had been treated with, or were eligible for, MD-ICS/LABA, comparing dual and triple therapies. We excluded cluster- and cross-over RCTs.We conducted a systematic review and network meta-analysis according to the previously published protocol. We used Cochrane's Screen4ME workflow to assess search results and Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. The primary outcome was steroid-requiring asthma exacerbations and asthma-related hospitalisations (moderate to severe and severe exacerbations).We included 17,161 patients with uncontrolled asthma from 17 studies (median duration 26 weeks; mean age 49.1 years; male 40%; white 81%; mean forced expiratory volume in 1 second (MEF 1)1.9 litres and 61% predicted). The quality of included studies was generally good except for some outcomes in a few studies due to high attrition rates. Medium-dose (MD) and high-dose (HD) triple therapies reduce steroid-requiring asthma exacerbations (hazard ratio (HR) 0.84 [95% credible interval (CrI) 0.71 to 0.99] and 0.69 [0.58 to 0.82], respectively) (high-certainty evidence), but not asthma-related hospitalisations, compared to MD-ICS/LABA. High-dose triple therapy likely reduces steroid-requiring asthma exacerbations compared to MD triple therapy (HR 0.83 [95% CrI 0.69 to 0.996], [moderate certainty]). Subgroup analyses suggest the reduction in steroid-requiring exacerbations associated with triple therapies may be only for those with a history of asthma exacerbations in the previous year but not for those without. High-dose triple therapy, but not MD triple, results in a reduction in all-cause adverse events (AEs) and likely reduces dropouts due to AEs compared to MD-ICS/LABA (odds ratio (OR) 0.79 [95% CrI 0.69 to 0.90], [high certainty] and 0.50 [95% CrI 0.30 to 0.84], [moderate certainty], respectively). Triple therapy results in little to no difference in all-cause or asthma-related serious adverse events (SAEs) compared to dual therapy (high certainty). The evidence suggests triple therapy results in little or no clinically important difference in symptoms or quality of life compared to dual therapy considering the minimal clinically important differences (MCIDs) and HD-ICS/LABA is unlikely to result in any significant benefit or harm compared to MD-ICS/LABA.Medium-dose and HD triple therapies reduce steroid-requiring asthma exacerbations, but not asthma-related hospitalisations, compared to MD-ICS/LABA especially in those with a history of asthma exacerbations in the previous year. High-dose triple therapy is likely superior to MD triple therapy in reducing steroid-requiring asthma exacerbations. Triple therapy is unlikely to result in clinically meaningful improvement in symptoms or quality of life compared to dual therapy considering the MCIDs. High-dose triple therapy, but not MD triple, results in a reduction in all-cause AEs and likely reduces dropouts due to AEs compared to MD-ICS/LABA. Triple therapy results in little to no difference in all-cause or asthma-related SAEs compared to dual therapy. HD-ICS/LABA is unlikely to result in any significant benefit or harm compared to MD-ICS/LABA, although long-term safety of higher rather than MD- ICS remains to be demonstrated given the median duration of included studies was six months. The above findings may assist deciding on a treatment option when asthma is not controlled with MD-ICS/LABA." @default.
- W4311503457 created "2022-12-26" @default.
- W4311503457 creator A5001137629 @default.
- W4311503457 creator A5021462482 @default.
- W4311503457 creator A5022076655 @default.
- W4311503457 creator A5028786727 @default.
- W4311503457 creator A5061532894 @default.
- W4311503457 date "2022-12-06" @default.
- W4311503457 modified "2023-10-02" @default.
- W4311503457 title "Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis" @default.
- W4311503457 cites W1857542727 @default.
- W4311503457 cites W1858555081 @default.
- W4311503457 cites W1883034450 @default.
- W4311503457 cites W1902576439 @default.
- W4311503457 cites W1950302841 @default.
- W4311503457 cites W1960462149 @default.
- W4311503457 cites W1962391690 @default.
- W4311503457 cites W1965973512 @default.
- W4311503457 cites W1966718625 @default.
- W4311503457 cites W1973413819 @default.
- W4311503457 cites W1982924223 @default.
- W4311503457 cites W1991683671 @default.
- W4311503457 cites W1996099244 @default.
- W4311503457 cites W2003706075 @default.
- W4311503457 cites W2007434636 @default.
- W4311503457 cites W2009191674 @default.
- W4311503457 cites W2012420530 @default.
- W4311503457 cites W2014186397 @default.
- W4311503457 cites W2019643126 @default.
- W4311503457 cites W2022145213 @default.
- W4311503457 cites W2024265404 @default.
- W4311503457 cites W2025828742 @default.
- W4311503457 cites W2033432863 @default.
- W4311503457 cites W2034106034 @default.
- W4311503457 cites W2035762677 @default.
- W4311503457 cites W2038550888 @default.
- W4311503457 cites W2039439214 @default.
- W4311503457 cites W2041512941 @default.
- W4311503457 cites W2045002632 @default.
- W4311503457 cites W2045066398 @default.
- W4311503457 cites W2046179969 @default.
- W4311503457 cites W2053298480 @default.
- W4311503457 cites W2057557604 @default.
- W4311503457 cites W2057765075 @default.
- W4311503457 cites W2059079741 @default.
- W4311503457 cites W2061683646 @default.
- W4311503457 cites W2063738853 @default.
- W4311503457 cites W2063905372 @default.
- W4311503457 cites W2064651388 @default.
- W4311503457 cites W2065770911 @default.
- W4311503457 cites W2070646431 @default.
- W4311503457 cites W2071270488 @default.
- W4311503457 cites W2075378073 @default.
- W4311503457 cites W2075917967 @default.
- W4311503457 cites W2079645048 @default.
- W4311503457 cites W2082273266 @default.
- W4311503457 cites W2085457639 @default.
- W4311503457 cites W2086167722 @default.
- W4311503457 cites W2086332783 @default.
- W4311503457 cites W2086416159 @default.
- W4311503457 cites W2091971768 @default.
- W4311503457 cites W2092982642 @default.
- W4311503457 cites W2093043874 @default.
- W4311503457 cites W2095088722 @default.
- W4311503457 cites W2096418647 @default.
- W4311503457 cites W2101045381 @default.
- W4311503457 cites W2104526821 @default.
- W4311503457 cites W2104675861 @default.
- W4311503457 cites W2104692335 @default.
- W4311503457 cites W2105984267 @default.
- W4311503457 cites W2112894410 @default.
- W4311503457 cites W2116458407 @default.
- W4311503457 cites W2116614343 @default.
- W4311503457 cites W2117993701 @default.
- W4311503457 cites W2118866729 @default.
- W4311503457 cites W2119011882 @default.
- W4311503457 cites W2119147796 @default.
- W4311503457 cites W2119922028 @default.
- W4311503457 cites W2121545123 @default.
- W4311503457 cites W2123309257 @default.
- W4311503457 cites W2126525937 @default.
- W4311503457 cites W2128450617 @default.
- W4311503457 cites W2130062856 @default.
- W4311503457 cites W2136797108 @default.
- W4311503457 cites W2140441261 @default.
- W4311503457 cites W2141501933 @default.
- W4311503457 cites W2143708606 @default.
- W4311503457 cites W2144555615 @default.
- W4311503457 cites W2145018753 @default.
- W4311503457 cites W2150529573 @default.
- W4311503457 cites W2153783329 @default.
- W4311503457 cites W2155217850 @default.
- W4311503457 cites W2156098321 @default.
- W4311503457 cites W2165166856 @default.
- W4311503457 cites W2165209634 @default.
- W4311503457 cites W2168316735 @default.
- W4311503457 cites W2185554765 @default.
- W4311503457 cites W2253786685 @default.
- W4311503457 cites W2289833205 @default.
- W4311503457 cites W2293620483 @default.